There has been a debate over the merits of vaccinating children who do not have underlying conditions as the chances of them developing a severe illness from COVID-19 are quite low, and this has to be balanced against the potential side effects of the vaccine. The use of the Moderna vaccine among children aged 5-11 is currently being assessed by the EMA.
This time, a study of 3,732 children in this particular age group showed none of those who received the vaccine contracted COVID-19 compared to four in the placebo group.
The EMA also approved the Moderna vaccine for use in the 12-17 age group in July. This means that, in this study, the vaccine was 90.7 per cent effective at preventing symptomatic COVID-19. They were given a smaller dose than those aged 12 and above, and of the 1,305 children receiving the vaccine, three developed COVID-19 compared with 16 out of the 663 children who received a placebo. For those aged 5-11 years-old a similar study was carried out with 2000 children.
0 kommentar(er)
